San Diego, CA (PRWEB) May 16, 2014
AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on safety alerts for Pradaxa.
As the FDA communicated on May 13, a recent FDA study that compared Pradaxa to Warfarin, among more than 134,000 Medicare patients, 65 years or older, and new users of blood-thinning drugs, Pradaxa was associated with a lower risk of clot-related strokes, bleeding in the brain, and death, but an increased risk of major gastrointestinal bleeding than Warfarin.
Based on these findings, Pradaxa is still considered by the FDA as having a favorable benefit to risk profile.
Taking into consideration the latest developments, AttorneyOne.com monitor daily and update the website providing accurate information on all relevant FDA safety alerts. Sean Burke, director of Media Relations at AttorneyOne.com, adds “we are determined to keep an eye on FDA announcements concerning Pradaxa and inform the public. For that reason", he continues, "our focus should squarely fall on investigating these safety alerts and getting the word out.”
As the Agency advises “Patients should not stop taking Pradaxa (or warfarin) without first talking with their health care professionals. Stopping the use of blood-thinning medications such as Pradaxa and warfarin can increase the risk of stroke and lead to permanent disability and death.” And the FDA adds “Health care professionals who prescribe Pradaxa should continue to follow the dosing recommendations in the drug label.”
AttorneyOne.com has further information on Pradaxa at the website including latest major drug and medical products law news.
Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2014/05/prweb11855380.htm